New! View global litigation for patent families

WO2000067787A3 - Hiv immunogenic compositions and methods - Google Patents

Hiv immunogenic compositions and methods

Info

Publication number
WO2000067787A3
WO2000067787A3 PCT/US2000/012495 US0012495W WO2000067787A3 WO 2000067787 A3 WO2000067787 A3 WO 2000067787A3 US 0012495 W US0012495 W US 0012495W WO 2000067787 A3 WO2000067787 A3 WO 2000067787A3
Authority
WO
Grant status
Application
Patent type
Prior art keywords
hiv
antigen
immunogenic
mammal
compositions
Prior art date
Application number
PCT/US2000/012495
Other languages
French (fr)
Other versions
WO2000067787A2 (en )
Inventor
Ronald B Moss
Original Assignee
Immune Response Corp Inc
Ronald B Moss
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/21Retroviridae, e.g. equine infectious anemia virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse Transcribing RNA Viruses
    • C12N2740/00011Reverse Transcribing RNA Viruses
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

The invention provides immunogenic compositions which enhance beta-chemokine levels in a mammal. The immunogenic compositions contain an HIV antigen, an isolated nucleic acid molecule containing an immunostimulatory sequence (ISS) and an adjuvant. The HIV antigen can be a whole-killed HIV virus devoid of outer envelope protein gp120. Alternatively, the HIV antigen can be a whole-killed HIV virus, or a p24 antigen. Also provided is a method of inhibiting AIDS, by enhancing beta-chemokine production in the mammal by administering to the mammal an immunogenic composition containing an HIV antigen, an isolated nucleic acid molecule containing an immunostimulatory sequence (ISS) and an adjuvant.
PCT/US2000/012495 1999-05-06 2000-05-05 Hiv immunogenic compositions and methods WO2000067787A3 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US13276299 true 1999-05-06 1999-05-06
US60/132,762 1999-05-06
US15066799 true 1999-08-25 1999-08-25
US60/150,667 1999-08-25

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20000932163 EP1176978A2 (en) 1999-05-06 2000-05-05 Hiv immunogenic compositions and methods
CA 2372960 CA2372960C (en) 1999-05-06 2000-05-05 Hiv immunogenic compositions and methods

Publications (2)

Publication Number Publication Date
WO2000067787A2 true WO2000067787A2 (en) 2000-11-16
WO2000067787A3 true true WO2000067787A3 (en) 2001-04-26

Family

ID=26830710

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/012495 WO2000067787A3 (en) 1999-05-06 2000-05-05 Hiv immunogenic compositions and methods

Country Status (3)

Country Link
EP (1) EP1176978A2 (en)
CA (1) CA2372960C (en)
WO (1) WO2000067787A3 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9028845B2 (en) 2001-06-21 2015-05-12 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same-IV
US9382545B2 (en) 2006-09-27 2016-07-05 Coley Pharmaceutical Gmbh CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity
US9598469B2 (en) 2001-07-05 2017-03-21 Novartis Vaccines And Diagnostics, Inc. HIV-1 south african subtype C env proteins

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
CA2328894A1 (en) 1998-05-22 1999-12-02 Loeb Health Research Institute At The Ottawa Hospital Methods and products for inducing mucosal immunity
DE60044236D1 (en) 1999-02-17 2010-06-02 Csl Ltd Immunogenic complex and methods with respect to these
ES2250151T3 (en) * 1999-06-29 2006-04-16 Glaxosmithkline Biologicals S.A. Cpg use as a vaccine adjuvant against HIV.
JP4188687B2 (en) 2000-12-27 2008-11-26 ダイナバックス テクノロジーズ コーポレイション Immune modulation polynucleotides and methods of use thereof
US20030044428A1 (en) * 2001-01-26 2003-03-06 Moss Ronald B. Method for treating an HIV-infected individual by combining immunization with structured interruption of anti-retroviral treatment
KR100991644B1 (en) 2001-08-17 2010-11-02 유니버시티 오브 아이오와 리써치 파운데이션 Combination Motif Immune Stimulatory Oligonucleotides with Improved Activity
WO2003028656A3 (en) 2001-10-03 2003-11-27 Chiron Corp Adjuvant compositions
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
JP2005532067A (en) * 2002-07-03 2005-10-27 コーリー ファーマシューティカル グループ,インコーポレイテッド The nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
EP2241325B1 (en) 2002-10-29 2012-02-08 Coley Pharmaceutical Group, Inc. Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
CA2502015A1 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5' cpg nucleic acids and methods of use
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
CN100546998C (en) 2002-12-23 2009-10-07 戴纳伐克斯技术股份有限公司 Immunostimulatory sequence oligonucleotides and methods of using the same
CA2535527A1 (en) * 2003-08-28 2005-03-10 The Immune Response Corporation Immunogenic hiv compositions and related methods
RU2393223C2 (en) 2004-10-20 2010-06-27 Коли Фармасьютикал Груп, Инк. Semi-soft c-class immunostimulatory oligonucleotides
WO2010051820A1 (en) * 2008-11-10 2010-05-14 Aarhus Universitet Multiplexed cytokine vaccination
EP2729125B1 (en) 2011-07-06 2017-12-13 GlaxoSmithKline Biologicals SA Oil-in-water emulsions that contain nucleic acids
WO2013006837A1 (en) 2011-07-06 2013-01-10 Novartis Ag Cationic oil-in-water emulsions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998040100A1 (en) * 1997-03-10 1998-09-17 Ottawa Civic Loeb Research Institute USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
WO1998055495A2 (en) * 1997-06-06 1998-12-10 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998040100A1 (en) * 1997-03-10 1998-09-17 Ottawa Civic Loeb Research Institute USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
WO1998055495A2 (en) * 1997-06-06 1998-12-10 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; MOSS R B ET AL: "Tumor necrosis factor alpha and human immunodeficiency virus -specific functional immune responses after immunization with Gp120 - depleted, inactivated HIV -1 in incomplete Freund 's adjuvant (REMUNE) in HIV -1-seropositive subjects.", XP002153410, retrieved from STN Database accession no. 1999211139 *
J HUM VIROL, (1998 JAN-FEB) 1 (2) 77-81. *
LANZA P ET AL: "Whole-killed gp120-depleted HIV-1 antigen in a murine model for prophylactic vaccination", VACCINE,GB,BUTTERWORTH SCIENTIFIC. GUILDFORD, vol. 16, no. 7, 1 April 1998 (1998-04-01), pages 727 - 731, XP004112262, ISSN: 0264-410X *
MOSS RONALD B ET AL: "In vitro immune function after vaccination with an inactivated, gp120-depleted HIV-1 antigen with immunostimulatory oligodeoxynucleotides.", VACCINE, vol. 18, no. 11-12, January 2000 (2000-01-01), pages 1081 - 1087, XP002153409, ISSN: 0264-410X *
SUN SIQUAN ET AL: "DNA as an adjuvant: Capacity of insect DNA and synthetic oligodeoxynucleotides to augment T cell responses to specific antigen", JOURNAL OF EXPERIMENTAL MEDICINE,TOKYO,JP, vol. 187, no. 7, 6 April 1998 (1998-04-06), pages 1145 - 1150, XP002148907, ISSN: 0022-1007 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9028845B2 (en) 2001-06-21 2015-05-12 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same-IV
US9598469B2 (en) 2001-07-05 2017-03-21 Novartis Vaccines And Diagnostics, Inc. HIV-1 south african subtype C env proteins
US9382545B2 (en) 2006-09-27 2016-07-05 Coley Pharmaceutical Gmbh CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity

Also Published As

Publication number Publication date Type
EP1176978A2 (en) 2002-02-06 application
WO2000067787A2 (en) 2000-11-16 application
CA2372960C (en) 2006-03-28 grant
CA2372960A1 (en) 2000-11-16 application

Similar Documents

Publication Publication Date Title
Mueller et al. Cordycepin analogs of 2', 5'-oligoadenylate inhibit human immunodeficiency virus infection via inhibition of reverse transcriptase
US7956043B2 (en) 5′ CpG nucleic acids and methods of use
US20080009455A9 (en) Immunostimulatory oligonucleotides
US20070142315A1 (en) Immunostimulatory oligoribonucleotides
US20050215501A1 (en) Methods and products for enhancing epitope spreading
WO2004016805A2 (en) Immunostimulatory nucleic acids
WO2008068638A2 (en) Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
WO2002079253A1 (en) Wti modified peptide
EP0362279A1 (en) Saponin adjuvant.
WO2004030608A3 (en) Nanoemulsion vaccines
WO2003086280A3 (en) Immunostimulatory g,u-containing oligoribonucleotides
WO2002096457A3 (en) Stable liquid formulations of antibodies
WO2001000232A2 (en) Use of cpg as an adjuvant for hiv vaccine
FR2388563A1 (en) Acellular vaccines containing capsular polysaccharides IMPROVED
WO2001093902A3 (en) Immunostimulatory rna/dna hybrid molecules
EP0480949A1 (en) Production of virus and purification of viral envelope proteins for vaccine use.
US20100260788A1 (en) Immune Stimulatory Oligoribonucleotide Analogs Containing Modified Oligophosphate Moieties
WO2002048157A3 (en) Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
Rocha et al. Determination of the immunization schedule for field trials with the synthetic malaria vaccine SPf 66
WO2005019258A3 (en) Compositions and methods for the treatment of immune related diseases
WO2002060926A3 (en) Hepatitis c tripeptide inhibitors
US20040170978A1 (en) Inhibitors of macromolecular activity
WO2003014338A1 (en) Process for producing inactivated virus envelope
WO2009115561A1 (en) Polynucleotides and chimaera polypeptides for releasing a polypeptide of interest combined with exosomes and use thereof for the production of immunogenic compositions
WO2001027263A1 (en) Modulate aptamer and method for detecting target protein by using the same

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 200108559

Country of ref document: ZA

Ref document number: 2001/08559

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/010784

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 49929/00

Country of ref document: AU

ENP Entry into the national phase in:

Ref country code: CA

Ref document number: 2372960

Kind code of ref document: A

Format of ref document f/p: F

Ref document number: 2372960

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000932163

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000932163

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase in:

Ref country code: JP